Although some call the strategy's failure rate 'too high,' it pushes the field a step closer to the 'holy grail' of a short alternative to the standard 24-week regimen. Medscape Medical News
Although some call the strategy’s failure rate ‘too high,’ it pushes the field a step closer to the ‘holy grail’ of a short alternative to the standard 24-week regimen. Medscape Medical News